High impact review reveals global paradigm shift in management of DCIS


What is the present view on how to manage the potential breast cancer precursor DCIS and why should we care? To answer these questions, group leader Jelle Wesseling has joined forces with experts from the USA, France and Canada for a comprehensive review of the available knowledge, current clinical practice, and ongoing developments. They publish their conclusions in the prestigious journal The Lancet . “This review makes it very clear that a substantial paradigm shift is ongoing towards de-escalation of DCIS treatment.

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.